Feng Bi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2647080/publications.pdf

Version: 2024-02-01

111	4,198	31 h-index	59
papers	citations		g-index
115	115	115	6669
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2015, 16, 619-629.	5.1	574
2	The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Communications, 2021, 41, 747-795.	3.7	323
3	Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial. Journal of Clinical Oncology, 2021, 39, 3002-3011.	0.8	171
4	Cholesterol metabolism: New functions and therapeutic approaches in cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188394.	3.3	166
5	Early-Course Unmedicated Schizophrenia Patients Exhibit Elevated Prefrontal Connectivity Associated with Longitudinal Change. Journal of Neuroscience, 2015, 35, 267-286.	1.7	153
6	Ferroptosis in the tumor microenvironment: perspectives for immunotherapy. Trends in Molecular Medicine, 2021, 27, 856-867.	3.5	141
7	Disrupted Functional Brain Connectome in Patients with Posttraumatic Stress Disorder. Radiology, 2015, 276, 818-827.	3.6	136
8	Two Patterns of White Matter Abnormalities in Medication-Naive Patients With First-Episode Schizophrenia Revealed by Diffusion Tensor Imaging and Cluster Analysis. JAMA Psychiatry, 2015, 72, 678.	6.0	134
9	Brain grey matter volume alterations in late-life depression. Journal of Psychiatry and Neuroscience, 2014, 39, 397-406.	1.4	123
10	Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Molecular Cancer, 2021, 20, 143.	7.9	117
11	Disorganization of white matter architecture in major depressive disorder: a meta-analysis of diffusion tensor imaging with tract-based spatial statistics. Scientific Reports, 2016, 6, 21825.	1.6	109
12	Altered Cortical Thickness Related to Clinical Severity But Not the Untreated Disease Duration in Schizophrenia. Schizophrenia Bulletin, 2015, 41, 201-210.	2.3	94
13	The IncRNA MALAT1 is a novel biomarker for gastric cancer metastasis. Oncotarget, 2016, 7, 56209-56218.	0.8	92
14	Plasma miR-122 and miR-192 as potential novel biomarkers for the early detection of distant metastasis of gastric cancer. Oncology Reports, 2014, 31, 1863-1870.	1.2	89
15	EGFR-PI3K-PDK1 pathway regulates YAP signaling in hepatocellular carcinoma: the mechanism and its implications in targeted therapy. Cell Death and Disease, 2018, 9, 269.	2.7	88
16	Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial. BMC Cancer, 2016, 16, 68.	1.1	82
17	Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019) Tj ETQq1 1 0.78	34314 rgB ⁷	Г/Qyerlock 1
18	Functional MRI reveals different response inhibition between adults and children with ADHD Neuropsychology, 2015, 29, 874-881.	1.0	68

#	Article	IF	Citations
19	Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma. Cancer Science, 2021, 112, 305-313.	1.7	62
20	Acetylcholine acts through M3 muscarinic receptor to activate the EGFR signaling and promotes gastric cancer cell proliferation. Scientific Reports, 2017, 7, 40802.	1.6	61
21	Alter between gut bacteria and blood metabolites and the anti-tumor effects of Faecalibacterium prausnitzii in breast cancer. BMC Microbiology, 2020, 20, 82.	1.3	61
22	CD44 acts through RhoA to regulate YAP signaling. Cellular Signalling, 2014, 26, 2504-2513.	1.7	59
23	Intrinsic disruption of white matter microarchitecture in first-episode, drug-naive major depressive disorder: A voxel-based meta-analysis of diffusion tensor imaging. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 76, 179-187.	2.5	56
24	Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice. Clinical Colorectal Cancer, 2019, 18, e117-e129.	1.0	53
25	Gray Matter Alterations in Post-Traumatic Stress Disorder, Obsessive–Compulsive Disorder, and Social Anxiety Disorder. Frontiers in Behavioral Neuroscience, 2015, 9, 219.	1.0	50
26	White Matter Abnormalities in Post-traumatic Stress Disorder Following a Specific Traumatic Event. EBioMedicine, 2016, 4, 176-183.	2.7	49
27	Characterization of brain blood flow and the amplitude of low-frequency fluctuations in major depressive disorder: A multimodal meta-analysis. Journal of Affective Disorders, 2017, 210, 303-311.	2.0	44
28	Abnormal dynamic functional connectivity of amygdalar subregions in untreated patients with first-episode major depressive disorder. Journal of Psychiatry and Neuroscience, 2018, 43, 262-272.	1.4	42
29	Clinical significance of circulating tumor cells in gastric cancer patients. Oncotarget, 2017, 8, 25713-25720.	0.8	39
30	A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBVâ€related HCC treated with sorafenib. Liver International, 2015, 35, 2147-2154.	1.9	38
31	Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial Journal of Clinical Oncology, 2020, 38, 4506-4506.	0.8	32
32	<p>Simvastatin Inhibits the Malignant Behaviors of Gastric Cancer Cells by Simultaneously Suppressing YAP and \hat{l}^2 -Catenin Signaling</p>. OncoTargets and Therapy, 2020, Volume 13, 2057-2066.	1.0	31
33	RHOA GTPase Controls YAP-Mediated EREG Signaling in Small Intestinal Stem Cell Maintenance. Stem Cell Reports, 2017, 9, 1961-1975.	2.3	29
34	Posttraumatic Stress Disorder: Structural Characterization with 3-T MR Imaging. Radiology, 2016, 280, 537-544.	3.6	28
35	Dipyridamole Enhances the Cytotoxicities of Trametinib against Colon Cancer Cells through Combined Targeting of HMGCS1 and MEK Pathway. Molecular Cancer Therapeutics, 2020, 19, 135-146.	1.9	28
36	Down regulation of lincRNA-p21 contributes to gastric cancer development through Hippo-independent activation of YAP. Oncotarget, 2017, 8, 63813-63824.	0.8	28

#	Article	IF	CITATIONS
37	Microstructural Abnormalities in Children with Post-traumatic Stress Disorder: A Diffusion Tensor Imaging Study at 3.0T. Scientific Reports, 2015, 5, 8933.	1.6	27
38	Ursodeoxycholic acid suppresses the malignant progression of colorectal cancer through TGR5-YAP axis. Cell Death Discovery, 2021, 7, 207.	2.0	26
39	P-Akt/miR-200 signaling regulates epithelial-mesenchymal transition, migration and invasion in circulating gastric tumor cells. International Journal of Oncology, 2014, 45, 2430-2438.	1.4	24
40	$ERR\hat{l}\pm$ suppression enhances the cytotoxicity of the MEK inhibitor trametinib against colon cancer cells. Journal of Experimental and Clinical Cancer Research, 2018, 37, 218.	3.5	24
41	Regulation of Ferroptosis by Amino Acid Metabolism in Cancer. International Journal of Biological Sciences, 2022, 18, 1695-1705.	2.6	23
42	The Rho GTPase RhoE is a p53-regulated candidate tumor suppressor in cancer cells. International Journal of Oncology, 2014, 44, 896-904.	1.4	21
43	White matter volume loss in amyotrophic lateral sclerosis: A meta-analysis of voxel-based morphometry studies. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 83, 110-117.	2.5	21
44	Simultaneously targeting SOAT1 and CPT1A ameliorates hepatocellular carcinoma by disrupting lipid homeostasis. Cell Death Discovery, 2021, 7, 125.	2.0	21
45	Inhibition of YAP reverses primary resistance to EGFR inhibitors in colorectal cancer cells. Oncology Reports, 2018, 40, 2171-2182.	1.2	20
46	Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III study. Future Oncology, 2018, 14, 2031-2044.	1.1	20
47	MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells. Molecular Medicine Reports, 2015, 11, 333-340.	1.1	19
48	Total neoadjuvant treatment (CAPOX plus radiotherapy) for patients with locally advanced rectal cancer with high risk factors: A phase 2 trial. Radiotherapy and Oncology, 2018, 129, 300-305.	0.3	19
49	Long noncoding RNA‑ATB promotes cell proliferation, migration and invasion in gastric cancer. Molecular Medicine Reports, 2018, 17, 1940-1946.	1.1	17
50	Standard CD44 modulates YAP1 through a positive feedback loop in hepatocellular carcinoma. Biomedicine and Pharmacotherapy, 2018, 103, 147-156.	2.5	17
51	miR-200b/c targets the expression of RhoE and inhibits the proliferation and invasion of non-small cell lung cancer cells. International Journal of Oncology, 2018, 53, 1732-1742.	1.4	17
52	MEK nuclear localization promotes YAP stability via sequestering \hat{I}^2 -TrCP in KRAS mutant cancer cells. Cell Death and Differentiation, 2019, 26, 2400-2415.	5.0	17
53	Sex differences in intrinsic brain functional connectivity underlying human shyness. Social Cognitive and Affective Neuroscience, 2015, 10, 1634-1643.	1.5	16
54	Cholesterol activates the Wnt/PCP-YAP signaling in SOAT1-targeted treatment of colon cancer. Cell Death Discovery, 2021, 7, 38.	2.0	16

#	Article	IF	Citations
55	Aspirin attenuates YAP and \hat{l}^2 -catenin expression by promoting \hat{l}^2 -TrCP to overcome docetaxel and vinorelbine resistance in triple-negative breast cancer. Cell Death and Disease, 2020, 11, 530.	2.7	15
56	Casp8 acts through A20 to inhibit PD‣1 expression: The mechanism and its implication in immunotherapy. Cancer Science, 2021, 112, 2664-2678.	1.7	15
57	Treatment Patterns and Outcomes in Chinese Patients with Gastric Cancer by <scp>HER2</scp> Status: A Noninterventional Registry Study (<scp>EVIDENCE</scp>). Oncologist, 2021, 26, e1567-e1580.	1.9	15
58	Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study. OncoTargets and Therapy, 2015, 8, 1363.	1.0	14
59	Expert consensus on maintenance treatment for metastatic colorectal cancer in China. Chinese Journal of Cancer, 2016, 35, 13.	4.9	14
60	The role of 5-HT metabolism in cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188618.	3.3	14
61	Zoledronic acid enhances the efficacy of the MEK inhibitor trametinib in KRAS mutant cancers. Cancer Letters, 2019, 442, 202-212.	3.2	12
62	An epithelial-mesenchymal transition-related 5-gene signature predicting the prognosis of hepatocellular carcinoma patients. Cancer Cell International, 2021, 21, 166.	1.8	12
63	Novel Bioluminescent Activatable Reporter for Src Tyrosine Kinase Activity in Living Mice. Theranostics, 2016, 6, 594-609.	4.6	11
64	S-1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial. Oncologist, 2019, 24, 591-e165.	1.9	11
65	First-line axitinib versus sorafenib in Asian patients with metastatic renal cell carcinoma: exploratory subgroup analyses of Phase III data. Future Oncology, 2019, 15, 53-63.	1.1	10
66	Phase I clinical trial of <scp>HC</scp> â€1119: A deuterated form of enzalutamide. International Journal of Cancer, 2021, 149, 1473-1482.	2.3	9
67	A multicenter phase II study of donafenib in patients with advanced hepatocellular carcinoma Journal of Clinical Oncology, 2017, 35, e15682-e15682.	0.8	9
68	Tumoral cavitation in colorectal cancer patients with unresectable lung metastasis treated with bevacizumab and chemotherapy. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1339-1346.	1.2	8
69	Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 <scp>CONCUR</scp> trial. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1307-1316.	1.4	8
70	Targeting SERT promotes tryptophan metabolism: mechanisms and implications in colon cancer treatment. Journal of Experimental and Clinical Cancer Research, 2021, 40, 173.	3.5	8
71	Clinicopathologic features, treatment, survival, and prognostic factors of combined hepatocellular and cholangiocarcinoma: A nomogram development based on SEER database and validation in multicenter study. European Journal of Surgical Oncology, 2022, 48, 1559-1566.	0.5	8
72	Chinese guidelines on the management of renal cell carcinoma (2015 edition). Chinese Clinical Oncology, 2016, 5, 12.	0.4	8

#	Article	IF	CITATIONS
73	A phase II trial of concurrent 3D-CRT/IMRT and oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) in gastric cancer patients with RO gastrectomy and D2 lymph node dissection. Gastric Cancer, 2016, 19, 245-254.	2.7	7
74	A Distinct Clinicopathological Feature and Prognosis of Young Gastric Cancer Patients Aged ≤5 Years Old. Frontiers in Oncology, 2021, 11, 674224.	1.3	7
75	The MEK inhibitors enhance the efficacy of sorafenib against hepatocellular carcinoma cells through reducing p-ERK rebound. Translational Cancer Research, 2019, 8, 1224-1232.	0.4	7
76	Curative-intent radiotherapy in patients with oligometastatic lesions from colorectal cancer. Medicine (United States), 2018, 97, e12601.	0.4	6
77	CMAB009 plus irinotecan versus irinotecanâ€only as secondâ€line treatment after fluoropyrimidine and oxaliplatin failure in <i>KRAS</i> wildâ€type metastatic colorectal cancer patients: promising findings from a prospective, openâ€label, randomized, phase III trial. Cancer Communications, 2019, 39, 1-13.	3.7	6
78	Primary malignant melanoma of lacrimal sac. International Journal of Ophthalmology, 2014, 7, 1069-70.	0.5	6
79	Autophagic sequestration of SQSTM1 disrupts the aggresome formation of ubiquitinated proteins during proteasome inhibition. Cell Death and Disease, 2022, 13, .	2.7	6
80	Efficacy and safety of chemotherapy combined with bevacizumab in Chinese patients with metastatic colorectal cancer: A prospective, multicenter, observational, non-interventional phase IV trial. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2021, 33, 490-499.	0.7	5
81	Complete Pathologic Response After Concurrent Treatment with Pembrolizumab and Radiotherapy in Metastatic Colorectal Cancer: A Case Report. OncoTargets and Therapy, 2021, Volume 14, 2555-2561.	1.0	5
82	Firstâ€line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component. Cancer Medicine, 2021, 10, 3388-3402.	1.3	5
83	Prospective randomized phase II study of FOLFIRI versus FOLFOX7 in advanced gastric adenocarcinoma: a Chinese Western Cooperative Gastrointestinal Oncology Group Study. Oncotarget, 2017, 8, 97890-97899.	0.8	5
84	A phase I study of adjuvant intensity-modulated radiotherapy with concurrent paclitaxel and cisplatin for cervical cancer patients with high risk factors. Medical Oncology, 2015, 32, 247.	1.2	4
85	Noninvasive Imaging of Ras Activity by Monomolecular Biosensor Based on Split-Luciferase Complementary Assay. Scientific Reports, 2017, 7, 9945.	1.6	4
86	Geranylgeranyl transferase 1 inhibitor GGTl‑298 enhances the anticancer effect of gefitinib. Molecular Medicine Reports, 2018, 18, 4023-4029.	1.1	4
87	PKM2 compensates for proteasome dysfunction by mediating the formation of the CHIPâ€HSP70â€BAG3 complexÂand the aggregation of ubiquitinated proteins. FASEB Journal, 2022, 36, e22121.	0.2	4
88	Patientâ€based costâ€effectiveness analysis of FOLFIRI versus FOLFOX7 for advanced gastric adenocarcinoma in China: A 4â€year prospective randomised phase II study. European Journal of Cancer Care, 2020, 29, e13196.	0.7	3
89	Chemoradiotherapy Is Inferior to Chemotherapy Alone in Adjuvant Setting for Signet Ring Cell Containing Gastric Cancer. Frontiers in Oncology, 2020, 10, 570268.	1.3	3
90	Bevacizumab Combined with Sâ€1 and Raltitrexed for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies: A Phase II Study. Oncologist, 2021, 26, e1320-e1326.	1.9	3

#	Article	IF	CITATIONS
91	Intramuscular Expression of Plasmid-Encoded FVII-Fc Immunoconjugate for Tumor Immunotherapy by Targeting Tumoral Blood Vessels and Cells. Frontiers in Oncology, 2021, 11, 638591.	1.3	3
92	Tracking Tumor Cells in Lymphatics in a Mice Xenograft Model by Magnetic Resonance Imaging. Molecular Imaging, 2012, 11, 7290.2012.00007.	0.7	2
93	Prognostic factors of intraperitoneal chemotherapy for peritoneal carcinomatosis of gastric cancer: A retrospective study from a single center. Oncology Letters, 2016, 11, 3501-3507.	0.8	2
94	A multicenter, phase II study of trastuzumab plus capecitabine and oxaliplatin (XELOX) as first-line chemotherapy for HER2-positive advanced gastric cancer: Update results of efficacy and toxicity Journal of Clinical Oncology, 2014, 32, 102-102.	0.8	2
95	Identification and characterization of inhibitory nanobody against p38l´. Biochemical and Biophysical Research Communications, 2022, 600, 60-66.	1.0	2
96	Safety, Efficacy, and Pharmacokinetics of Metatinib Tromethamine Tablet in Patients with Advanced Refractory Solid Tumors: A Phase I Clinical Trial. Oncologist, 2021, 26, 649.	1.9	1
97	Efficacy of lenvatinib plus pembrolizumab in hepatocellular carcinoma with metachronous lung metastasis: a report of two cases. Tumori, 2021, 107, 030089162110333.	0.6	1
98	Effects of regorafenib therapy on health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) in the phase III CONCUR trial Journal of Clinical Oncology, 2015, 33, 697-697.	0.8	1
99	Prospective randomized phase II study of FOLFIRI versus FOLFOX7 in advanced gastric adenocarcinoma: A Chinese Western Cooperative Gastrointestinal Oncology Group study Journal of Clinical Oncology, 2016, 34, 1-1.	0.8	1
100	Axitinib versus sorafenib as second‑line therapy in Asian patients with metastatic renal cell carcinoma (mRCC): Results from a registrational study Journal of Clinical Oncology, 2012, 30, LBA4537-LBA4537.	0.8	1
101	Phase I study of HC-1119, an androgen receptor inhibitor: Results from the dose escalation and expansion cohorts Journal of Clinical Oncology, 2018, 36, e17021-e17021.	0.8	1
102	Alter between gut bacteria and blood metabolites and the anti-tumor effects of Faecalibacterium prausnitzii in breast cancer Journal of Clinical Oncology, 2020, 38, e12575-e12575.	0.8	1
103	Axitinib versus sorafenib as secondâ€'line therapy in Asian patients with metastatic renal cell carcinoma (mRCC): Results from a registrational study Journal of Clinical Oncology, 2012, 30, LBA4537-LBA4537.	0.8	О
104	A prospective, multicenter, observational study of bevacizumab in combined with chemotherapy as first-line or second-line treatment in Chinese metastatic colorectal cancer Journal of Clinical Oncology, 2016, 34, e15012-e15012.	0.8	0
105	A phase II trial of total neoadjuvant treatment (TNT) (Capox plus radiotherapy) for local advanced rectal cancer patients with high risk factors Journal of Clinical Oncology, 2017, 35, e15025-e15025.	0.8	0
106	A prospective multicenter observational study of bevacizumab for the treatment of metastatic colorectal cancer in Chinese patients (Obtain study) Journal of Clinical Oncology, 2018, 36, e15560-e15560.	0.8	0
107	Tumoral cavitation in colorectal cancer patients with lung metastasis treated with bevacizumab and chemotherapy Journal of Clinical Oncology, 2018, 36, e15565-e15565.	0.8	0
108	Trastuzumab plus docetaxel and capecitabine for first-line treatment of Her2-positive advanced gastric cancer: A phase II, multi-center, open-label, single-arm study Journal of Clinical Oncology, 2018, 36, 4045-4045.	0.8	O

#	Article	IF	CITATIONS
109	Aspirin attenuates YAP and \hat{l}^2 -catenin expression by promoting \hat{l}^2 -TrCP to overcome docetaxel and vinorelbine resistance in triple-negative breast cancer Journal of Clinical Oncology, 2020, 38, e13099-e13099.	0.8	O
110	Tislelizumab plus cisplatin/carboplatin and gemcitabine versus placebo plus cisplatin/carboplatin and gemcitabine in Chinese patients with advanced urothelial carcinoma: A phase III trial in progress Journal of Clinical Oncology, 2020, 38, TPS588-TPS588.	0.8	0
111	Tanshinone II improves distribution and anti-tumor efficacy of pegylated liposomal doxorubicin via normalizing the structure and function of tumor vasculature in hepa1-6 hepatoma mice model. Journal of Traditional Chinese Medicine, 2018, 38, 815-822.	0.1	0